BofA Securities Maintains Immatics(IMTX.US) With Buy Rating, Cuts Target Price to $13

Moomoo NewsJan 7 07:36 ET · Ratings

Immatics Price Target Lowered to $13 From $15 at BofA

TipRanksJan 7 07:21 ET

12 Health Care Stocks Moving In Friday's Pre-Market Session

BenzingaJan 3 16:05 ET

Clear Street Launches Healthcare & Biotechnology Equity Research

BusinesswireDec 17, 2024 14:00 ET

Bristol Myers Squibb Terminates Agreements With Immatics Due To Ongoing Portfolio Prioritization Efforts Within BMS For Allogeneic Programs; Collaboration With BMS Under The 2019 Multi-Target TCR-T Strategic Collaboration Agreement Remains Ongoing

BenzingaDec 16, 2024 09:42 ET

Mizuho Securities Maintains Immatics(IMTX.US) With Buy Rating, Maintains Target Price $16

Moomoo NewsDec 16, 2024 06:31 ET · Ratings